Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 12/20 | 0.36 |
| ▸ | RARG | P13631 | 12/20 | 0.36 |
| ▸ | RARA | P10276 | 11/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340315 | 0.90 | RARB (0.46) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6341156 | 0.88 | RARA (0.42) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6340700 | 0.86 | ACACB (0.36) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6342474 | 0.85 | RARA (0.35) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6339231 | 0.83 | RARA (0.33) | RARBRARGRARA | |
| SCHEMBL6340122 | 0.83 | BACE1 (0.37) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6341267 | 0.80 | RARB (0.42) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL7471196 | 0.78 | CYP3A4 (0.56) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6338642 | 0.77 | RARA (0.36) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6339579 | 0.76 | RARB (0.45) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849658-B2 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2005-02-01 | — | — | US | claimed |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | claimed |
| EP-0977749-B1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-03-13 | — | — | EP | claimed |
| EP-0977749-A1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development (FR) | 2000-02-09 | — | — | EP | claimed |
| WO-1998056783-A1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 1998-12-17 | — | — | WO | claimed |
| US-6849658-B2 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2005-02-01 | — | — | US | disclosed |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | disclosed |
| EP-0977749-B1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-03-13 | — | — | EP | disclosed |
| US-6346546-B1 | COMPOUNDS HAVING MARKED ACTIVITY IN FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION; TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-12 | — | — | US | disclosed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | disclosed |
| EP-0977749-A1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development (FR) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998056783-A1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | AR, SRR, MC3R | RARB 120/4885RARG 136/4885RARA 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.